Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Massachusetts General Hospital · Dana-Farber/Harvard Cancer Center · +29 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,646
total citations
- FWCI
- 131.43
- Percentile
- 100%
- References
- 39
Citations per year
Authors
24- AXAndrew X. ZhuCorresponding
Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center
- YKYoon‐Koo Kang
Asan Medical Center, University of Ulsan
- CYChia‐Jui Yen
National Cheng Kung University Hospital, National Cheng Kung University
- RSRichard S. Finn
University of California, Los Angeles
- PRPeter R. Galle
Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz
Topics & keywords
Topics
Keywords
- Ramucirumab
- Medicine
- Sorafenib
- Hepatocellular carcinoma
- Internal medicine
- Placebo
- Clinical endpoint
- Cirrhosis
No related works found for this paper.